Alnylam Pharmaceuticals gains FDA approval for Amvuttra in ATTR-CM, boosting revenue prospects. Click here to read an ...

U.S. Food and Drug Administration approved Alnylam's drug to treat a rare and deadly heart disease on Thursday, allowing the ...

Alnylam Pharmaceuticals Inc. won expanded US approval for a heart drug that could be the biggest boon yet for the 23-year-old ...

Alnylam's Amvuttra enters ATTR-CM drug race, and Expedition Therapeutics seeks to bring Chinese drugs to the U.S.

Alnylam Pharmaceuticals shares rose 10% Friday after the company nabbed FDA approval to sell its drug Amvuttra to a larger ...

The U.S. Food and Drug Administration has approved Alnylam Pharmaceuticals drug Amvuttra to treat transthyretin amyloid ...

Heart disease patients now have another treatment option. The U.S. Food and Drug Administration has approved Alnylam ...

Alnylam Pharmaceuticals' amyloidosis drug Amvuttra received Food and Drug Administration approval for an expanded indication.

Alnylam’s drug, vutrisiran, was approved for patients with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce ...

Alnylam (ALNY) announced the FDA approval of the supplemental New Drug Application for its RNAi therapeutic, Amvuttra, for the treatment of the ...

Canaccord raised the firm’s price target on Alnylam (ALNY) to $390 from $385 and keeps a Buy rating on the shares. The firm noted they ...